Following “lower than expected demand,” Nestlé is exploring strategic options for Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first and only drug approved by the US FDA for the treatment of peanut allergy in children. Possible causes for the slow uptake of Palforzia include the COVID-19 pandemic, frequent doctor’s visits with additional time when escalating […]
Archives
Excipient enhanced growth (EEG) is progressing through toxicological studies and showing promise for treatment of asthma and lung cancer by delivering active molecules to target sites in the lungs. This article discusses development of two candidates, budesonide and gemcitabine, for local lung delivery using this formulation approach in combination with traditional spray drying for the […]
The United States Centers for Disease Control and Prevention (CDC) has published a report in the Annals of Allergy, Asthma and Immunology that offers recommendations and resources to assist allergists and immunologists in supporting patients as they become affected by climate change. In two articles, Healio interviewed two of the three report authors. They discuss […]
The SABINA study of SABA inhaler usage and risk of asthma exacerbations, funded by AstraZeneca, is the largest real-world observational data analysis of asthma inhaler therapy and has evaluated more than one million patients across 40 countries. In addition, at Queen Mary University of London, a study of more than 700,000 patient records evaluated SABA […]
Local treatment of lung cancer by the inhalation route is an emerging therapeutic area, particularly for early stages of the disease when the cancer is localized in the lung tissue. This article outlines manufacturing and formulation considerations for local treatment of lung cancer by dry powder inhaler and highlights three recent case studies. The article […]
AAFA has launched the Health Equity Advancement and Leadership (HEAL) program to address findings from its 2020 report about asthma disparities in America. Each year, the HEAL Innovation program will award funding and resources to four local, pilot, community-based asthma programs tailored to at-risk populations most impacted by asthma and will focus on needs of […]
HEI undertook the Global Burden of Disease from Major Air Pollution Sources (GBD-MAPS) project to determine which air pollution sources or fuels contribute most to outdoor PM2.5 concentrations and their associated health burden. The study provides the first comprehensive estimates at global, regional and national levels, which can help inform policy. A variety of results […]
Greater associations between risk of mortality and long-term exposures to relatively low concentrations of fine particulate matter (PM2.5) have been reported. Recognizing “more stringent air quality standards and guidelines will likely be considered,” The Health Effects Institute has funded three studies—in the United States, Europe and Canada—“to explore health effects from air pollution exposure at […]
Researchers from Tulane University School of Medicine analyzed operating costs of a partnership between school-based health centers (SBHCs) and a local allergist providing asthma care for students. Results showed the program was sustainable and cost-neutral and did not rely on grant funding. When grant funding for the program expired, the partners investigated and negotiated contracting […]
The UK National Health Service (NHS) has launched the PRECISION Asthma Mobile Clinic provided by AstraZeneca, which will partner with local NHS respiratory services to accelerate delivery of asthma care. More than one in 20 patients in the UK postponed emergency care due to the COVID-19 pandemic and more than a quarter of patients avoided […]